





a**b**

Figure S1. Pan-caspase inhibitor failed to reverse TRAIL-mediated inhibition of joint inflammation.

a. C57BL/6 mice were immunized with a cocktail of 5 monoclonal antibodies to type II collagen (3 mg/mouse, IV) on day 0 followed by an LPS on day 3 (50 mg/mouse, IP). From day 3 post-immunization, mice were treated with vehicle or TRAIL (50 mg/mouse, IP) daily. The hind paw thickness (left panel) and clinical score (right panel) among groups were measured at the indicated time points (n= 10 in each group). * $p < 0.05$, ** $p < 0.01$, by Student's *t*-test. b. C57BL/6 mice were immunized with a cocktail of 5 monoclonal antibodies to type II collagen (3 mg/mouse, IV) on day 0 followed by an LPS on day 3 (50 mg/mouse, IP). From day 3 post-immunization, mice were treated with vehicle, TRAIL (50 mg/mouse, IP) plus vehicle, or TRAIL plus z-VAD-fmk (20 μ g/mouse, IP) daily. The hind paw thickness (left panel) and clinical score (right panel) among groups were measured at the indicated time points (n= 10 in each group). * $p < 0.05$, ** $p < 0.01$, by Student's *t*-test.